Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Asymmetric Michael Addition. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel tridentate nitrogen ligand for asymmetric Michael addition. High yield, low catalyst loading. Reliable supply for pharma intermediates.
Novel catalytic route for pregabalin intermediates avoids toxic reagents. Enhances supply chain reliability and reduces manufacturing costs for pharmaceutical partners.
Discover a cost-effective synthesis route for homophenylalanine derivatives via Michael addition and reduction, offering high purity and scalable manufacturing for pharmaceutical intermediates.
Patent CN102838526B enables high-yield organocatalytic synthesis. Delivers cost reduction in pharmaceutical intermediate manufacturing and reliable supply chain continuity.
Novel 3-step route for Pregabalin avoids resolution waste. High ee value up to 99.6%. Cost-effective manufacturing for pharma intermediates.
Efficient asymmetric Michael addition for pharmaceutical intermediates using novel Ru-diamine complexes. Reduces cost and improves purity for API manufacturing.
Patent CN105985292B enables mild asymmetric catalysis. Delivers high-purity pharmaceutical intermediates with substantial cost reduction and supply chain reliability.
Patent CN102180886B details a novel enantioselective route to Galanthamine using organocatalysis, offering high purity and scalable manufacturing for pharmaceutical supply chains.
Patent CN107312010A reveals a high-yield sitagliptin synthesis route. Offers cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN100584459C reveals a novel metal-free organocatalyst enabling dual-handed synthesis of gamma-nitro ketones with >99% ee, offering significant cost reduction and supply chain reliability.
Patent CN104974055B reveals high stereoselectivity synthesis. Offers cost reduction and supply reliability for pharmaceutical intermediates manufacturing globally.
Patent CN1626501A details a high-efficiency ruthenium-catalyzed asymmetric Michael addition for producing optically active nitro and cyano compounds, offering significant cost reduction in API manufacturing.
Patent CN107311911B reveals a novel chemical route for Niraparib intermediates, replacing costly enzymatic methods with scalable asymmetric synthesis for reliable supply.
Novel patent CN119735538B details high-purity Brivaracetam production. This route offers significant cost reduction and supply chain reliability for global pharmaceutical intermediate manufacturers.
Patent CN104860911B reveals a metal-free synthesis for chiral 3,4-dihydrocoumarin derivatives. Discover cost-effective, high-purity pharmaceutical intermediate manufacturing solutions.
Patent CN107188874A reveals efficient Cu-catalyzed Michael addition. High ee, mild conditions for pharma intermediates.
Patent CN119613463A reveals a copper-catalyzed route for high-purity R-musk ketone, offering significant cost reduction and supply chain reliability for fragrance manufacturers.
Novel chiral squaramide catalyzed route for Ruxolitinib intermediate. High yield, >98% ee. Cost-effective scale-up for pharma supply chains.
Patent CN108147973B details a novel thiourea-catalyzed route for ECPPA, offering superior stereoselectivity and simplified processing for ACE inhibitor manufacturing.
Patent CN102167689B details a low-cost, scalable route for chiral warfarin using amine catalysis, offering significant supply chain advantages for anticoagulant manufacturing.